Older Men
Should Pass on Getting Prostate Cancer Treatment
The advice
to detect and treat cancers at the first opportunity may not apply to older men
with prostate tumors, according to the latest study
By Alexandra Sifferlin. In TIME
The Way We
Think about Cancer Must Evolve
Right now,
as you read these words, your life is in danger. Somewhere within the vast
self-contained micro-universe known as you, in one and possibly more of your
trillions of cells, something is going wrong. A vital protein, perhaps, is
being altered or destroyed as one cell divides to create another. The mutated
cell, an incorrect version of its former self, will continue to multiply, compounding
and extending its grotesque influence as an intruder and usurper, bent on its
own self- preservation at your expense. It has become cancer.
By Mark Wolverton. In Wired
American
Cancer Society Celebrates 100 Years of Progress
One million
cancer deaths avoided since 1990s, group says.
In U.S.
Cancer: Drug
for an 'undruggable' protein
Scientists
have long aimed to develop drugs against the cancer-associated protein KRAS,
but without success. An approach that targets the oncoprotein's cellular
localization reignites lost enthusiasm.
By Nicole M. Baker & Channing J. Der. In Nature
Promising
New Approach to Treatment of Lung Cancer
Researchers
have developed a new drug delivery system that allows inhalation of
chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal
tests it appears to reduce the systemic damage done to other organs while
significantly improving the treatment of lung tumors.
In Science
Daily
Cancer : optimisme à géométrie
variable
Le regard sur le cancer profondément
évolué ces dernières décennies à la faveur des progrès de la médecine.
Désormais, ce n’est plus seulement la fatalité et le pessimisme qui dominent
lorsqu’on évoque ces pathologies. L’enquête d’opinion PACE (Patient Acces and
Cancer Care Excellence) menée sous l’égide des laboratoires Lilly dans six pays
(Allemagne, Italie, Royaume-Uni, Japon, Etats-Unis et France) auprès, dans
chaque état, d’une centaine de patients, d'une centaine de professionnels de
santé et de cinq cent personnes dans la population générale, confirme cette
évolution.
Par Léa Crébat. Dans JIM
Métastases osseuses du cancer de la
prostate : la FDA
donne son accord à Xofigo
L'agent, le radium-223 dichloride
(connu sous le nom d'alpharadin), a reçu une autorisation de mise sur le marché
(AMM) de la Food
and Drug Administration (FDA) le 15 mai. Il sera commercialisé par les
laboratoires Bayer sous le nom de Xofigo® dans le traitement du cancer de la
prostate avec métastase(s) osseuse(s) uniquement, chez les hommes ayant
préalablement bénéficié d'une autre thérapie visant à influer sur le taux de
testostérone
Par Zosia
Chustecka, Aude Lecrubier. Dans Medscape
Aucun commentaire:
Enregistrer un commentaire